Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy.

Ko, Eun-Ju; Kwag, Eun-Bin; Park, Ji Hye; Park, So-Jung; Son, Ji-Woong; Yoon, Seong-Hun; Shin, Seong-Hun; Yoo, Hwa-Seung

Ko, Eun-Ju; Kwag, Eun-Bin; Park, Ji Hye; Park, So-Jung; Son, Ji-Woong; Yoon, Seong-Hun; Shin, Seong-Hun; Yoo, Hwa-Seung.

Affiliation

Ko EJ; Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea.
Kwag EB; Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea.
Park JH; Seoul Korean Medicine Hospital of Daejeon University, Seoul, Republic of Korea.
Park SJ; Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea.
Son JW; Konyang University Hospital, Daejeon, Republic of Korea.
Yoon SH; Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
Shin SH; Kosin University Gospel Hospital, Pusan, Republic of Korea.
Yoo HS; Daejeon Korean Medicine Hospital of Daejeon University, Daejeon, Republic of Korea.

Integr Cancer Ther ; 20: 15347354211037917, 2021.

Article de En | MEDLINE | ID: mdl-34409891

Sujet(s)
Mots clés

EGFR-TKI; HAD-B1; afatinib; disease control rate; non-small cell lung cancer

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome pulmonaire non à petites cellules / Tumeurs du poumon Type d'étude: Clinical_trials / Diagnostic_studies Limites: Humans Langue: En Journal: Integr Cancer Ther Sujet du journal: NEOPLASIAS / TERAPEUTICA Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google